John Sturges, MD
Neuromusculoskeletal Medicine & OMM · Coeur D Alene, IDNPI 1164507166
Payments from drug & device makers
Across 491 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$929
- Lilly USA, LLC$712
- Amgen$658
- Johnson & Johnson$602
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$532
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,84499%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,565 |
| AstraZeneca | 46 | $929 |
| Lilly USA, LLC | 42 | $712 |
| Amgen(2 entities) | 31 | $658 |
| Johnson & Johnson(2 entities) | 18 | $602 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $532 |
| Novo Nordisk | 32 | $521 |
| Pfizer | 33 | $509 |
| Exact Sciences | 25 | $427 |
| Bayer | 21 | $392 |
| Novartis | 11 | $265 |
| Abbott | 12 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $181 |
| Sanofi-aventis U.S. LLC | 10 | $144 |
| Zimvie Inc. | 1 | $134 |
| Boehringer Ingelheim | 5 | $118 |
| Eisai Inc. | 6 | $109 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Corcept Therapeutics | 4 | $96 |
| Radius Health, Inc. | 6 | $91 |
| Amarin Pharma, Inc. | 6 | $90 |
| Biohaven Pharmaceuticals, Inc. | 5 | $68 |
| Fidia Pharma USA Inc. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $43 |
| Biomerieux Inc | 2 | $43 |
| GSK | 2 | $40 |
| Therapeuticsmd, Inc. | 2 | $30 |
| Mayne Pharma Commercial LLC | 3 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromusculoskeletal medicine & omm providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 44 | $53,773 |
| EliquisApixaban | 40 | $32,797 |
| JardianceEmpagliflozin | 14 | $18,604 |
| OzempicSemaglutide | 12 | $17,763 |
| FarxigaDapagliflozin Propanediol | 24 | $16,323 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $6,333 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $2,407 |
| Atorvastatin Calcium | 207 | $2,188 |
| Estradiol | 13 | $1,801 |
| Levothyroxine Sodium | 137 | $1,705 |
| Omeprazole | 115 | $1,542 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,482 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $1,472 |
| Memantine Hcl | 20 | $1,186 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $712 | $53,77344 claims |
| PfizerEliquis | $509 | $32,79740 claims |
| Boehringer IngelheimJardiance | $118 | $18,60414 claims |
| Novo NordiskOzempic | $521 | $17,76312 claims |
| AstraZenecaFarxiga | $929 | $16,32324 claims |
| AbbVieSynthroid | $1,565 | $75019 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $25 | $74837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other neuromusculoskeletal medicine & omm in Coeur D Alene
- Zachariah JensenBoise$502
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.